Search Results 361-370 of 17378 for alopecia
... alopecia, vitiligo, and the laboratory values defined in the inclusion criteria: Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case ...
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); however, alopecia, sensory ...
... alopecia and other non-clinically significant adverse events (AEs); Patients with no known brain metastasis at baseline must have baseline brain imaging ...
Received chemotherapy or radiotherapy within 3 weeks prior to randomization or those who have not recovered to =< grade 1 adverse events (other than alopecia) ...
... alopecia, ototoxicity and neuropathy. Patients must not be receiving any other investigational anti-cancer agents while on study. Patients must not have ...
Betamethasone topical cream, gel, lotion, and ointment are used to help relieve redness, itching, swelling, or other discomforts caused by certain skin ...
previously administered agent. - Note: individuals with any grade neuropathy or alopecia are an exception to this criterion and will qualify for the study ...
Comparing treatments for pediatric atopic dermatitis. Studying the impact of climate change on skin conditions related to flooding. Discovering new allergens in ...
... alopecia, weight changes and grade I or II lymphopenia. Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study (6 ...
... alopecia and =< grade 2 neuropathy, which are allowed; Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.